PPMD, Sarepta Join Forces on Genetic Testing Programme for DMD patients
The major news broke out in the field of Genetic testing programme as Parent Project Muscular Dystrophy (PPMD) and Sarepta Therapeutics, Inc. have successfully started a nationwide programme from PPMD to help individuals with Duchenne muscular dystrophy (DMD) in professionally accessing genetic testing. This persuasive programme would be administered professionally by PPMD, a leading voice for patients and families impacted by Duchenne. It is also reported that major support for the initiative would be specially offered by Sarepta, a developer of innovative RNA-based therapeutics.
By this innovative programme, called Decode Duchenne, PPMD would provide genetic testing at no cost to eligible patients who are unable to access testing due to several barriers.
The major barrier would be lack of or insufficient insurance coverage. The sources say that Decode Duchenne would anticipate launching it successfully in the fourth quarter of 2013. This rather would occur through PPMD’s DuchenneConnect, an online resource in registry for patients and families affected by Duchenne with their healthcare providers.
Therefore for patients with Duchenne, genetic testing would utilize to identify the genetic mutation and confirm the diagnosis. More over the genetic testing could be utilized to analyze a patient’s eligibility for certain clinical trials. In addition there are some advantageous of testing, in some cases patients who are unable to access genetic testing through their potent insurance provider.